Seville – 25th april 2016

Last March, the Center for Industrial Technological Development (CDTI) granted INFARMADE a grant for the development of the Project of Research and Development called “REFORMULATION OF A MEDICATION TO INCREASE ITS STABILITY”. The purpose of This project is the development of new tools that allow to expand the armamentarium for the prevention and treatment of nausea and vomiting in cancer patients.

The general objective is the development of new forms pharmaceuticals from an active ingredient that is part of a new generation antiemetic drugs, which, after their first tests, offer signs of greater efficacy compared to current treatments. of this In this way, INFARMADE will be able to offer new optimized pharmaceutical forms, more stable, secure, easy and comfortable to administer than those available to today. In addition, such features could improve its performance and effectiveness in the treatment of cancer patients, to ensure that the therapeutic guidelines are met and also reduce production costs of such dosage forms. Finally, if the results of this project are satisfactory, the new optimized dosage forms will be used in clinical trials designed to assess their efficacy and safety.